FDA Approves Luspatercept as First-Line Anemia Treatment in Patients With Lower-Risk MDS There is no standard treatment in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for patients ...
Please provide your email address to receive an email when new articles are posted on . Olutasidenib monotherapy or combination therapy may help certain patients with myelodysplastic syndrome achieve ...
Successful Management of Neutropenic Sepsis Is Key to Better Survival of Patients With Blood Cancer in Sri Lanka: Real-World Data From the Resource-Limited Setting Myelodysplastic syndromes (MDS) ...
A rare mutation on the BCL6-corepressor gene correlated with worse overall survival in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, allogenic stem cell ...
Younger patients with relapsed MDS may benefit from DLI post-stem cell transplant, improving overall survival rates. DLI is associated with graft-versus-host disease, but its impact on prognosis is ...
The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition considered incurable without transplantation, according to a new clinical study ...
Myelodysplastic syndromes (MDS) and autoimmune conditions can overlap, and each may raise the risk of the other. Up to 30% of people with MDS also have an autoimmune disorder. Autoimmune conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results